It seems someone else sees some merit in this! Holding for the future...! Low trading big gains - back to 40c sometime soon when more info trickles out?
Recent research results published by scientists at Syracuse University in New York1 confirm Apollo Life Sciences’ (ASX: AOP) approach to delivering insulin in an oral form. The Syracuse research team demonstrated that attaching insulin molecules to vitamin B12 molecules can overcome some of the obstacles to delivering the drug orally. The results suggest that vitamin B12 molecules may help to protect insulin from digestion by enzymes in the stomach as well as facilitate the transport of insulin across the small intestine into the blood stream. Apollo’s Head of Drug Delivery, Dr Michael Luke, said the Syracuse findings endorse a key component of Apollo’s oral insulin delivery technology – utilising vitamin B12 as a transporter molecule. “In addition to using vitamin B12 molecules to carry insulin across the intestinal wall, Apollo’s trademarked drug delivery technology called Oradel™ is able to deliver a large dose of insulin per vitamin B12 molecule by encapsulating it in a matrix of nanoparticles which act as a delivery satchel. “Insulin molecules are entrapped within a matrix coated with vitamin B12, and are pulled through the wall of the small intestine using the body's natural transport system for vitamin B12,” Dr Luke said. According to Dr Luke, the company has amassed a substantial data set demonstrating the effectiveness of its oral insulin against subcutaneously injected insulin in diabetic rodents. “Our research data shows that Apollo’s Oradel™ technology can lower blood glucose levels to within normal range for up to 12 hours in diabetic rats. "While it is an important step to be able to deliver insulin across the gut wall, it also essential to deliver doses that are large enough to have a therapeutic effect," he said. Apollo is currently preparing for Phase 1 trial of its Oradel™ technology in relation to oral insulin. In the critical areas of uniformity of particle size and the joining of vitamin B12 molecules to nanoparticles, Apollo has successfully established quality control and assurance processes for the Phase 1 trial.
AOP Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
